Showing results (1-10 of 165) with videos related to
Sort By:
Pageof 17
Clinical Pharmacology and Therapeutics|December 1, 1982
Comparison of intravenous and oral verapamil dosingM J Reiter, D G Shand, E L PritchettClinical Pharmacology and Therapeutics|April 1, 1983
Verapamil plasma binding: relationship to alpha 1-acid glycoprotein and drug efficacyF X McGowan, M J Reiter, E L Pritchett, et al.Chest|April 1, 1982
Electrocardiogram recording by telephone in antiarrhythmic drug trialsE L Pritchett, J M Zimmerman, K F Hammill, et al.Computers and Biomedical Research, an International Journal|August 1, 1983
A system for the analysis of long-term electrocardiographic studies in clinical research and trainingA A Lastra, E L Pritchett, M J Reiter, et al.The American Journal of Cardiology|July 1, 1983
Efficacy, safety, and pharmacokinetics of a concentration-maintaining regimen of intravenous pirmenolM J Reiter, S C Hammill, D G Shand, et al.The American Journal of Cardiology|October 1, 1982
Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimenM J Reiter, D G Shand, L M Aanonsen, et al.Pacing and Clinical Electrophysiology : PACE|July 22, 1998
Evolution and revolution in drug labeling: regulation of antiarrhythmic drugs by the Food and Drug Administration 1962-1996E L PritchettClinical Pharmacology and Therapeutics|December 1, 1982
Pirmenol kinetics and effective oral doseS C Hammill, D G Shand, F E Harrell, et al.The American Journal of Cardiology|November 1, 1983
Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardiaE L Pritchett, S C Hammill, M J Reiter, et al.Molecular and Cellular Endocrinology|April 1, 1988
Detection of corticosteroid type I binding sites in heartC A Barnett, E L PritchettPageof 17